Physician profile
Daniel M Rusu
NPI 1154374023
$752.29
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $122 · 2021: $57.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $172.13 | 2019 | |
| Livanova USA, INC. | $131.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.02 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $78.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.47 | 2019-2020 | |
| Gilead Sciences, INC. | $38.52 | 2021 | |
| Jazz Pharmaceuticals INC. | $36.38 | 2019-2021 | |
| Biomerieux INC | $26.50 | 2019-2020 | |
| Grifols USA, LLC | $22.55 | 2019 | |
| Glaxosmithkline, LLC. | $22.49 | 2019 | |
| Csl Behring | $21.94 | 2019 | |
| Mayne Pharma Commercial LLC | $20.09 | 2020 | |
| Chiesi USA, INC. | $18.41 | 2020 | |
| Insulet Corporation | $14.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rusu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.